{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:52:21Z","timestamp":1790873541853,"version":"4.1.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Psoriatic Arthritis (PsA) is a multifactorial disease, and predicting remission is challenging. Machine learning (ML) is a promising tool for building multi-parametric models to predict clinical outcomes. We aimed at developing a ML algorithm to predict the probability of remission in PsA patients on treatment with Secukinumab (SEC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PsA patients undergoing SEC treatment between September 2017 and September 2020 were retrospectively analyzed. At baseline and 12-month follow-up, we retrieved demographic and clinical characteristics, including Body Mass Index (BMI), disease phenotypes, Disease Activity in PsA (DAPSA), Leeds Enthesitis Index (LEI) and presence\/absence of comorbidities, including fibromyalgia and metabolic syndrome. Two random feature elimination wrappers, based on an eXtreme Gradient Boosting (XGBoost) and Logistic Regression (LR), were trained and validated with 10-fold cross-validation for predicting 12-month DAPSA remission with an attribute core set with the least number of predictors. The performance of each algorithm was assessed in terms of accuracy, precision, recall and area under receiver operating characteristic curve (AUROC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One-hundred-nineteen patients were selected. At 12 months, 20 out of 119 patients (25.21%) achieved DAPSA remission. Accuracy and AUROC of XGBoost was of 0.97 \u00b1 0.06 and 0.97 \u00b1 0.07, overtaking LR (accuracy 0.73 \u00b1 0.09, AUROC 0.78 \u00b1 0.14). Baseline DAPSA, fibromyalgia and axial disease were the most important attributes for the algorithm and were negatively associated with 12-month DAPSA remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A ML approach may identify SEC good responders. Patients with a high disease burden and axial disease with comorbid fibromyalgia seem challenging to treat.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.917939","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T06:38:43Z","timestamp":1656311923000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab"],"prefix":"10.3389","volume":"13","author":[{"given":"Vincenzo","family":"Venerito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Tangaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of Life in Psoriatic Arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing Psoriatic Arthritis: Focusing on Patients With Psoriasis at Increased Risk of Transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B3","first-page":"68","article-title":"Epidemiological Profile of non-Infectious Uveitis From the Rheumatologist\u2019s Perspective: A Survey From Two Tertiary Referral Centres in Italy","volume":"36","author":"Lopalco","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.737079","article-title":"Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk","volume":"8","author":"Novelli","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e001600","DOI":"10.1136\/rmdopen-2021-001600","article-title":"Secukinumab Provides Sustained Improvement in Signs and Symptoms and Low Radiographic Progression in Patients With Psoriatic Arthritis: 2-Year (End-of-Study) Results From the FUTURE 5 Study","volume":"7","author":"Mease","year":"2021","journal-title":"RMD Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001519","article-title":"Effectiveness and Safety of Secukinumab in 608 Patients With Psoriatic Arthritis in Real Life: A 24-Month Prospective, Multicentre Study","volume":"7","author":"Ramonda","year":"2021","journal-title":"RMD Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217251","article-title":"Secukinumab Efficacy in Patients With PsA is Not Dependent on Patients\u2019 Body Mass Index","volume":"81","author":"Pantano","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2020.1266","article-title":"Remission, Low Disease Activity and Improvement of Pain and Function in Psoriatic Arthritis Patients Treated With IL-12\/23 and IL-17 Inhibitors. A Multicenter Prospective Study","volume":"72","author":"Perrotta","year":"2020","journal-title":"Reumatismo"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.01.012","article-title":"Remission in Psoriatic Arthritis: Definition and Predictors","volume":"50","author":"Alharbi","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000522008","article-title":"Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study","author":"Ortolan","year":"2022","journal-title":"Dermatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez505","article-title":"Comorbid Fibromyalgia Impairs the Effectiveness of Biologic Drugs in Patients With Psoriatic Arthritis","volume":"59","author":"Iannone","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05728-1","article-title":"High Disease Relapse After bDMARD Spacing in Psoriatic Arthritis Compared to Rheumatoid Arthritis and Axial Spondyloarthritis Patients: Real-Life Data From BIOPURE Registry","volume":"40","author":"Fornaro","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001720","article-title":"A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents","volume":"16","author":"Venerito","year":"2021","journal-title":"JCR: J Clin Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-020-02583-x","article-title":"A Convolutional Neural Network With Transfer Learning for Automatic Discrimination Between Low and High-Grade Synovitis: A Pilot Study","volume":"16","author":"Venerito","year":"2021","journal-title":"Intern Emerg Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random Forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach Learn"},{"key":"B16","unstructured":"BuitinckL\n            LouppeG\n            BlondelM\n            PedregosaF\n            MuellerA\n            GriselO\n          API Design for Machine Learning Software: Experiences From the Scikit-Learn Project. Arxiv:13090238 [Cs]2013"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3414\/ME14-04-0003","article-title":"Youden\u2019s Index and the Weight of Evidence","volume":"54","author":"Hughes","year":"2015","journal-title":"Methods Inf Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190054","article-title":"Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome","volume":"46","author":"Lubrano","year":"2019","journal-title":"J Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22404","article-title":"Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis","volume":"66","author":"Helliwell","year":"2014","journal-title":"Arthritis Care Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24560","article-title":"Real-World 6 and 12-Month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis Patients in 13 European Countries","author":"Michelsen","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"keac129","DOI":"10.1093\/rheumatology\/keac129","article-title":"Systemic Glucocorticoid Use and the Occurrence of Flares in Psoriatic Arthritis and Psoriasis: A Systematic Review","author":"Vincken","year":"2022","journal-title":"Rheumatol (Oxf)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"151948","DOI":"10.1016\/j.semarthrit.2021.12.012","article-title":"Enthesitis in Patients With Psoriatic Arthritis and Axial Spondyloarthritis - Data From the Danish Nationwide DANBIO Registry","volume":"52","author":"Mathew","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.679009","article-title":"Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study","volume":"8","author":"Alonso","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210662","article-title":"Evaluation of Clinical Diagnosis of Axial Psoriatic Arthritis (PsA) or Elevated Patient-Reported Spine Pain in Corevitas\u2019 PsA\/Spondyloarthritis Registry","volume":"49","author":"Ogdie","year":"2022","journal-title":"J Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.917939\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T06:38:47Z","timestamp":1656311927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.917939\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2022.917939"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.917939","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"article-number":"917939"}}